LSK Global PS-DKSH Korea Concludes MOU for

                                        Strategic Expansion of the Pharmaceutical Market Services

- South Korea’s leading CRO LSK Global PS signsMOU with Asia No.1 market expansion service provider DKSH Korea

- LSK Global PS and DKSH Korea expected todemonstrate more advanced capabilities in the healthcare field through expandedservice opportunities

[September 21, 2017] South Korea’s leading contract research organization(CRO) LSK Global PS (LSK Global Pharma Services Co., Ltd.) announced onSeptember 21^st to have signed a Memorandum of Understanding (MOU)with DKSH Korea (aka DKSH) for cooperation and expansion of the pharmaceutical market.The two companies will cooperate in a mutually beneficiall manner to providespecialized business expansion services to help Korean pharmaceutical companiesbring drugs from foriegn pharmaceutical companies and clinical trials to Koreaas well as introduce Korean drugs to Asian markets.

The MOU ceremony proceeded with the presence of key representatives of bothcompanies, including Young-Jack Lee CEO of LSK Global PS and In-Hee Lee HealthCare Division Director of DKSH. The main contents of the MOU signed by LSKGlobal PS and DKSH are as follows: to share opportunities in providing clinicaltrials-related services, to share opportunities in providing servicespharmacovigilance-related services, to share opportunities in providing druglicensing services, to share opportunities in providing domestic products tothe Asian market, and other business progress that is deemed necessary forcooperation between the two parties.  

Through the MOU, LSK Global PS and DKSH are expected to result positiveoutcomes such as expanding the scope of service and enhancing efficiency bymaximizing the integrated service infrastructure synergy from domestic as wellas overseas pharmaceutical market expansion services of clniical trials of bothcompanies.

# # #